| Question |
Location of Relevant Content |
| 1 |
Community preparedness |
| 2 |
Community preparedness |
| 3 |
What type of pathology do cholinesterase inhibitors cause? |
| 4 |
What type of pathology do cholinesterase inhibitors cause? |
| 5 |
Nicotine acetylcholine receptors |
| 6 |
Nicotine acetylcholine receptors |
| 7 |
Nicotine acetylcholine receptors |
| 8 |
Muscarinic acetylcholine receptors |
| 9 |
What is the cholinergic toxidrome? |
| 10 |
Effects on routine laboratory tests |
| 11 |
Differential diagnosis |
| 12 |
Signs and symptoms: differences in pediatric cases |
| 13 |
Who is at risk for exposure? The exposure history |
| 14 |
Who is at risk for exposure? The exposure history |
| 15 |
Effects on routine laboratory tests |
| 16 |
Management strategy 2: Supportive care |
| 17 |
Management strategy 3: Medications - Atropine |
| 18 |
Management strategy 3: Medications |
| 19 |
Management strategy 3: Medications |
| 20 |
Management strategy 3: Medications |
| 21 |
Management strategy 3: Medications – 2-PAM |
| 22 |
Management strategy 3: Medications |
| 23 |
Management strategy 3: Medications |
| 24 |
Management strategy 3: Medications - Diazepam |
| 25 |
Syrup of ipecac, gastric lavage, cathartics, and activated charcoal |
| 26 |
The intermediate syndrome |
| 27 |
Organophosphate-induced delayed neuropathy (OPIDN) |
| 28 |
Organophosphorus ester-induced chronic neurotoxicity (OPICN) |
| 29 |
Other issues related to cholinesterase inhibitor toxicity |
| 30 |
The intermediate syndrome |
| 31 |
Muscarinic acetylcholine receptors |
| 32 |
Clinical findings are due to a mixture of nicotinic and muscarinic effects |
| 33 |
Clinical findings are due to a mixture of nicotinic and muscarinic effects |
| 34 |
Who is at risk for exposure? The exposure history |
| 35 |
What are cholinesterase inhibitors? |
| 36 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
| 37 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
| 38 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
| 39 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
| 40 |
The cholinergic toxidrome: Clinical findings in cholinesterase inhibitor toxicity are due to a mixture of nicotinic and muscarinic effects.
The cholinergic toxidrome: Signs and Symptoms: differences in pediatric cases |
| 41 |
Management strategy 2: supportive care |
| 42 |
Laboratory Assessment of the Cholinergic Toxidrome: Red Blood Cell (RBC) and Serum Cholinesterase Levels |
| 43 |
Laboratory Assessment of the Cholinergic Toxidrome: Direct Measurement of Cholinesterase Inhibitors and Their Metabolic Byproduct |
| 44 |
Management of the Cholinergic Toxidrome: Management Strategy 1: Prevention of Secondary Exposure |
| 45 |
Public Health and Medico-Legal Issues |